<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130943">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01668277</url>
  </required_header>
  <id_info>
    <org_study_id>1000026525</org_study_id>
    <nct_id>NCT01668277</nct_id>
  </id_info>
  <brief_title>Effects of Saline on Circulation in Children</brief_title>
  <official_title>Effects of Hypertonic Saline on the Pulmonary Circulation in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary hypertensive crisis is a life-threatening condition, in which the blood pressure
      in the pulmonary artery, vein, and capillaries. Infusion of hypertonic saline solutions
      expand the circulating volume, thus allowing more blood to flow and reducing pressure in the
      artery, vein, and capillaries. Furthermore, infusion of hypertonic saline has been shown to
      reduce both systemic and pulmonary vascular resistances in adults. If the pulmonary vascular
      resistance decreases more or to the same degree as the systemic resistance, infusion of
      hypertonic saline may prove beneficial in the treatment of pulmonary hypertensive crisis.
      The primary objective of this study is to investigate how a clinically relevant dose of
      hypertonic saline affects the systemic and pulmonary circulations in children undergoing
      cardiac catheterization during general anesthesia. This study hypothesizes that an infusion
      of hypertonic saline over 10 minutes will reduce the pulmonary vascular resistance more than
      the systemic vascular resistance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pulmonary Vascular Resistance Index</measure>
    <time_frame>Change from Baseline in Pulmonary Vascular Resistance Index after 1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pulmonary vascular resistance index, a hemodynamic measurement, will be performed during the cardiac catherization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic Vascular Resistance Index</measure>
    <time_frame>Change from Baseline in Systemic Vascular Resistance Index after 1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>Systemic vascular resistance index, a hemodynamic measurement, will be performed during the cardiac catherization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Index</measure>
    <time_frame>Change from Baseline in Cardiac Index after 1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cardiac index, a hemodynamic measurement, will be performed during the cardiac catherization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Gas</measure>
    <time_frame>Average over 1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>Effect on blood hemoglobin, plasma potassium and sodium, measured on a blood gas analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Volume</measure>
    <time_frame>Average over 1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>Effect on plasma volume calculated from the change in blood hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Natriuretic Peptide</measure>
    <time_frame>Average over 1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>Effect on atrial natriuretic peptide</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Pulmonary Hypertensive Crisis</condition>
  <arm_group>
    <arm_group_label>3 ml/kg  7.2% NaCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The test fluids 7.2% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 ml/kg 0.9% NaCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The test fluids 0.9% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 ml/kg 0.9% NaCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The test fluids 0.9% NaCl 20 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7.2% NaCl</intervention_name>
    <arm_group_label>3 ml/kg  7.2% NaCl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% NaCl</intervention_name>
    <arm_group_label>3 ml/kg 0.9% NaCl</arm_group_label>
    <arm_group_label>20 ml/kg 0.9% NaCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children who have had a heart transplant and are scheduled for elective
             endomyocardial biopsies during general anaesthesia

          -  Age &gt; 2 years

        Exclusion Criteria:

          -  Plasma Na &lt; 130 mmol/l or &gt;150 mmol/l

          -  Refusal of consent

          -  An estimated pulmonary arterial pressure which is greater than or equal to 66% of
             systemic blood pressure

          -  Children with heart failure (right and/or left), i.e clinical  suspicion by either a
             cardiologist or an anesthesiologist of inability to tolerate a fluid bolus of 3 ml/kg
             7.2% NaCl corresponding to an expansion of the circulatory volume by approximately 9%
             (see the section on safety), which is the equivalent of infusion approximately 20
             ml/kg 0.9% NaCl over 10 minutes.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Taylor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Taylor, MD</last_name>
    <phone>(416)813-7654</phone>
    <phone_ext>2453</phone_ext>
    <email>katherine.taylor@sickkids.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Taylor, MD</last_name>
      <phone>(416)813-7654</phone>
      <phone_ext>2453</phone_ext>
      <email>katherine.taylor@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Jens Aage Kolsen Petersen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Redington, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lee Benson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Taylor, FANZCA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital For Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 31, 2013</lastchanged_date>
  <firstreceived_date>August 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Katherine Taylor</investigator_full_name>
    <investigator_title>Staff Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Hypertensive Crisis</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Hypertonic Saline</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertensive Encephalopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
